Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Mometasone

From Wikipedia, the free encyclopedia
(Redirected fromMometasone furoate)
Steroid medication

Pharmaceutical compound
Mometasone
Clinical data
Trade namesNasonex, Asmanex, Elocon, others[1]
Other namesLAS-41002,9α,21-Dichloro-11β,17α-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17α-(2-furoate)
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration
Topical,inhalation (nasal spray)
Drug classCorticosteroid;Glucocorticoid
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNasal spray is virtually undetectable in plasma; but systemic availability is comparable tofluticasone[9]
Protein binding98% to 99%
MetabolismLiver
Eliminationhalf-life5.8 hours
Identifiers
  • (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.125.600Edit this at Wikidata
Chemical and physical data
FormulaC22H28Cl2O4 for mometasone
C27H30O6Cl2 as furoate
3D model (JSmol)
  • CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C

  • as furoate: CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C
  • InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 checkY
  • Key:QLIIKPVHVRXHRI-CXSFZGCWSA-N checkY

  • as furoate: InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
  • Key:WOFMFGQZHJDGCX-ZULDAHANSA-N
 ☒NcheckY (what is this?)  (verify)

Mometasone, also known asmometasone furoate, is asteroid (specifically, aglucocorticoid) medication used to treat certainskin conditions,hay fever, andasthma.[10][11][12] Specifically it is used to prevent rather than treat asthma attacks.[10] It can be applied to the skin, inhaled, or used in the nose.[10][11][12] Mometasonefuroate, not mometasone, is used in medical products.[13]

Common side effects when used for asthma include headache, sore throat, andthrush.[10] It is therefore recommended to rinse the mouth after use.[10] Long-term use may increase the risk forglaucoma andcataracts.[10] Common side effects when used in the nose includeupper respiratory tract infections andnose bleeds.[12] Common side effects when applied on the skin includeacne,skin atrophy, and itchiness.[11] It works by decreasinginflammation.[10]

Mometasone furoate was patented in 1981 and came into medical use in 1987.[14] It is on theWorld Health Organization's List of Essential Medicines[15] and is available as ageneric medication.[16][17] In 2023, it was the 272nd most commonly prescribed medication in the United States, with more than 800,000 prescriptions.[18][19]

Medical uses

[edit]

Mometasone furoate is used in the treatment of inflammatory skin disorders (such aseczema[20] andpsoriasis) (topical form),allergic rhinitis (such ashay fever) (topical form),asthma (inhalation form)[21][22] for patients unresponsive to less potentcorticosteroids, and penilephimosis.[23] In terms of steroid strength, it is more potent thanhydrocortisone, and less potent thandexamethasone.[24]

Some low-quality evidence suggests the use of mometasone for symptomatic improvement in children withadenoid hypertrophy.[25]

Mometasone is used to alleviate inflammation and itchiness in skin conditions that respond to treatment with glucocorticoids such as psoriasis and atopic dermatitis.[26][27]

Nasal Mometasone is used in people over two years of age to diminish the symptoms of hay fever (seasonal allergic rhinitis) and other allergies (perennial rhinitis), including nasal congestion, discharge, pruritus, sneezing, and treatnasal polyps.[6]

It is not useful for thecommon cold.[28]

Asthma

[edit]

Mometasone furoate can be used withformoterol for the treatment of asthma, due to its anti-inflammatory properties.[25][22]

Contraindications

[edit]
icon
This sectiondoes notcite anysources. Please helpimprove this section byadding citations to reliable sources. Unsourced material may be challenged andremoved.(February 2024) (Learn how and when to remove this message)

People should not use inhaled mometasone or mometasonenasal spray if they have:

  • glaucoma or cataracts
  • hypersensitivity, or are allergic to any ingredient in mometasone

Those who are using mometasone nasal or inhaled for a long period of time (e.g. more than three months) should get regular eye exams to check forglaucoma andcataracts and should take precautions to avoid infections such as taking a vitamin D supplement, staying away from those with an infection (chickenpox, measles, colds or flu, COVID-19), washing foods, hand washing and calling a family doctor at the first sign of a severe infection.

People should not use mometasone topical (skin cream) if:

  • hypersensitive or allergic to any ingredient in the skin cream

The risks of Mometasone furoate to the baby during pregnancy cannot be ruled out.

Side effects

[edit]
icon
This sectiondoes notcite anysources. Please helpimprove this section byadding citations to reliable sources. Unsourced material may be challenged andremoved.(January 2022) (Learn how and when to remove this message)

The nasal spray form of mometasone may cause the followingside effects:

Serious side effects include:Thrush (fungal infection in the nose or throat), slow wound healing, eye problems such as glaucoma or cataracts, weakened immune system (immunodeficiency) which causes increased susceptibility to infections andadrenal insufficiency.

The inhaled form of mometasone for asthma may cause the following side effects:

  • headache
  • stuffy or runny nose
  • dry throat
  • swelling of nose, throat and sinuses
  • flu-like symptoms
  • painful menstrual periods

Serious side effects may include allergic reactions (anaphylaxis), increased risk ofosteoporosis, glaucoma and cataracts, thrush in the mouth or throat, growth retardation in children,bronchospasms, adrenal insufficiency and weakened immune system which causes increased susceptibility to infections.

The topical (skin cream) version may cause:

  • burning and itching at the application site
  • acne
  • changes in skin color
  • dryness at the application site
  • skin sores

The only serious side effect that is known with mometasone topical isadrenal insufficiency.

Pharmacology

[edit]

Pharmacodynamics

[edit]

Mometasone furoate reduces inflammation by causing several effects:[6][29][30]

  • Reversing the activation of inflammatory proteins
  • Activating the secretion of anti-inflammatory proteins
  • Stabilizing cell membranes
  • Decreasing the influx of inflammatory cells

In addition to theglucocorticoid properties of mometasone furoate, it is a very potentagonist of theprogesterone receptor as well as apartial agonist of themineralocorticoid receptor.[31]

Mechanism of action

[edit]
Mometasone — the metabolite of mometasone furoate.

Mometasone, like other corticosteroids, possesses anti-inflammatory, antipruritic, and vasoconstrictive properties. For allergies, corticosteroids reduce the allergic reactions in various types of cells (mastocytes and eosinophils) that are responsible for allergic reactions. Mometasone and other corticosteroids circulate in the blood easily, crossing cellular membranes and binding with cytoplasmic receptors, resulting in the transcription and synthesis of proteins. It also inhibits the actions of the enzymecytochrome P450 2C8 which participates in the activity of monooxygenase.[32]

The inflammation is reduced by decreasing the liberation ofhydrolase acids ofleukocytes, the prevention of the accumulation ofmacrophages in the sites of inflammation, the interference with the adhesion of leukocytes tocapillary walls, the reduction of the permeability of the capillary membranes and consequentlyedema, the reduction of complementary components, inhibition of histamine andkinin liberation, and interference with scar tissue formation.[33] The proliferation of fibroblasts and collagen deposits is also reduced. It is believed that the action of corticosteroid anti-inflammatory agents is bound to inhibitive proteins ofphospholipase A2, collectively called lipocortins. The lipocortins, in turn, control the biosynthesis of potent mediators of inflammation as theprostaglandins andleukotrienes, inhibiting the liberation of the molecular precursors ofarachidonic acid. Intranasal mometasone alleviates symptoms such asrhinorrhea aquosa,nasal congestion, nasal drip, sneezing, and pharyngeal itching. Topical administration applied to the skin reduces the inflammation associated with chronic or acute dermatosis.

Although mometasone furoate does not have significant systemic immunomodulatory effects, it can be considered a local immunosuppressive drug because clinical studies have shown reductions (vs. baseline ) in neutrophils (a white blood cell) in the nasal mucosa.[citation needed] It could be also considered an antihistamine along with its glucocorticoid effects because it significantly reduces histamine and eosinophil cationic protein levels.[citation needed]

Pharmacokinetics

[edit]

Metabolism

[edit]

Extensive metabolic hepatic metabolism of mometasone furoate to multiple metabolites occurs. No principal metabolites are detectable in plasma. Afterin vitro incubation, one of the minor metabolites formed is furoate 6β-hydroxymometasone. In human hepatic microsomes, the formation of these metabolites is regulated byCYP3A4.[6]

Mometasone

[edit]

Mometasone by itself is asynthetic,steroidalglucocorticoid orcorticosteroid that was never marketed.[34][35][36] The C17αfuroateester of mometasone, is the marketed medication.[34][35][36] Mometasone furoate acts as aprodrug of mometasone.[37] In addition to its glucocorticoid activity, mometasone also has very potentprogestogenic activity and acts as apartial agonist of themineralocorticoid receptor.[31]

Society and culture

[edit]

Availability

[edit]

As of 2016, mometasone furoate is available worldwide in formulations for nasal, oral inhalation, and topical administration, for human and veterinary use, either as a single active agent or in combination with other medications, under many brand names.[1]

Combinations

[edit]

The following combination medications are available as of 2022:[38]

CombinationCommercial NameNotes
azelastineNasaflex
clotrimazole andgentamicinMometamax, MometavetVeterinary use
clotrimazole andmupirocinDerma Q
florfenicol andterbinafineClaroVeterinary use
formoterolDulera, Hexaler Bronquial Duo, Zenhale
fusidic acidBactirest-M, Dermotil Fusid, Momate-F
gentamicin andposaconazoleMometamax UltraVeterinary use
hydroquinone andtretinoinAcnezac-MH
miconazoleElica M, Elica-M, and Sensicort-F
mupirocinSensicort-B
orbifloxacin andposaconazolePosatex, Posatex voor honden, Posatex für HundeVeterinary use
salicylic acidCortimax-S, Elicasal, Elocom Plus, Elosalic, Mezo-S, Momate-S, Momesalic,

Momtas-S, Monsalic, Sensicort-S

terbinafineCutizone-T, Mezo-T, MomelomTerbi-Humanity
tiotropiumTiomom

References

[edit]
  1. ^ab"International brands for Mometasone". Drugs.com.Archived from the original on 17 November 2016. Retrieved17 November 2016.
  2. ^"Mometasone Use During Pregnancy".Drugs.com. 14 February 2020.Archived from the original on 26 October 2020. Retrieved1 April 2020.
  3. ^"Nasonex Allergy mometasone furoate 50 micrograms/ actuation (as monohydrate) aqueous nasal spray (215798)".Therapeutic Goods Administration (TGA). 15 July 2020. Retrieved22 August 2024.
  4. ^"Nasonex aqueous nasal spray mometasone furoate 50 microgram/actuation (as monohydrate) spray bottle (77112)".Therapeutic Goods Administration (TGA). 10 October 2023. Retrieved22 August 2024.
  5. ^"Noumed Mometasone Hayfever & Allergy Relief (Noumed Pharmaceuticals PTY LTD)".Therapeutic Goods Administration (TGA). 13 September 2024. Retrieved15 September 2024.
  6. ^abcd"Nasonex- mometasone furoate spray, metered".DailyMed. 26 January 2011.Archived from the original on 5 November 2022. Retrieved19 June 2022.
  7. ^"Nasonex- mometasone furoate spray".DailyMed. 15 December 2022.Archived from the original on 17 April 2023. Retrieved17 April 2023.
  8. ^"List of nationally authorised medicinal products"(PDF). European Medicines Agency.Archived(PDF) from the original on 7 March 2023. Retrieved6 March 2023.
  9. ^Tayab ZR, Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ, et al. (November 2007)."Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate".British Journal of Clinical Pharmacology.64 (5):698–705.doi:10.1111/j.1365-2125.2007.02919.x.PMC 2203259.PMID 17509041.
  10. ^abcdefg"Mometasone Furoate Monograph for Professionals".Drugs.com. American Society of Health-System Pharmacists.Archived from the original on 7 October 2016. Retrieved11 March 2019.
  11. ^abc"Mometasone Furoate topical Monograph for Professionals".Drugs.com. American Society of Health-System Pharmacists.Archived from the original on 5 August 2020. Retrieved11 March 2019.
  12. ^abc"Mometasone Furoate eent Monograph for Professionals".Drugs.com. American Society of Health-System Pharmacists.Archived from the original on 30 April 2016. Retrieved11 March 2019.
  13. ^"Mometasone".DrugBank.Archived from the original on 29 June 2019. Retrieved30 April 2020.
  14. ^Fischer J, Ganellin CR (2006).Analogue-based Drug Discovery. John Wiley & Sons. p. 488.ISBN 978-3-527-60749-5.
  15. ^World Health Organization (2021).World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization.hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  16. ^"Competitive Generic Therapy Approvals".U.S.Food and Drug Administration (FDA). 29 June 2023. Archived fromthe original on 29 June 2023. Retrieved29 June 2023.
  17. ^British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 265.ISBN 978-0-85711-338-2.
  18. ^"The Top 300 of 2023".ClinCalc.Archived from the original on 17 August 2025. Retrieved17 August 2025.
  19. ^"Mometasone Drug Usage Statistics, United States, 2014 - 2023".ClinCalc. Retrieved17 August 2025.
  20. ^Lax SJ, Harvey J, Axon E, Howells L, Santer M, Ridd MJ, et al. (Cochrane Skin Group) (March 2022)."Strategies for using topical corticosteroids in children and adults with eczema".The Cochrane Database of Systematic Reviews.2022 (3) CD013356.doi:10.1002/14651858.CD013356.pub2.PMC 8916090.PMID 35275399.
  21. ^Tan RA, Corren J (December 2008)."Mometasone furoate in the management of asthma: a review".Therapeutics and Clinical Risk Management.4 (6):1201–8.doi:10.2147/TCRM.S3261.PMC 2643101.PMID 19337427.
  22. ^abBousquet J (May 2009). "Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma".International Journal of Clinical Practice.63 (5):806–19.doi:10.1111/j.1742-1241.2009.02003.x.PMID 19392928.S2CID 2040993.
  23. ^Khope S (March 2010). "Topical mometasone furoate for phimosis".Indian Pediatrics.47 (3): 282.PMID 20371899.
  24. ^Williams DM (2005). "What does potency actually mean for inhaled corticosteroids?".The Journal of Asthma.42 (6):409–17.doi:10.1081/jas-57878.PMID 16293535.S2CID 43138631.
  25. ^abPassali D, Spinosi MC, Crisanti A, Bellussi LM (2 May 2016)."Mometasone furoate nasal spray: a systematic review".Multidisciplinary Respiratory Medicine.11: 18.doi:10.1186/s40248-016-0054-3.PMC 4852427.PMID 27141307.
  26. ^Green C, Colquitt JL, Kirby J, Davidson P, Payne E (November 2004)."Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation".Health Technology Assessment.8 (47): iii, iv,1–120.doi:10.3310/hta8470.PMID 15527669.
  27. ^Prakash A, Benfield P (January 1998). "Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders".Drugs.55 (1):145–63.doi:10.2165/00003495-199855010-00009.PMID 9463794.S2CID 46976211.
  28. ^"Mometasone Nasal Spray: MedlinePlus Drug Information".MedlinePlus. 19 March 2020.Archived from the original on 20 March 2020. Retrieved19 March 2020.Mometasone nasal spray should not be used to treat symptoms (e.g., sneezing, stuffy, runny, itchy nose) caused by the common cold. Mometasone nasal spray is in a class of medications called corticosteroids. It works by blocking the release of certain natural substances that cause allergy symptoms.
  29. ^Nurse's Drug Handbook 2010. Jones & Bartlett Learning. 15 July 2009. p. 677.ISBN 978-0-7637-7900-9.
  30. ^Kavuru MS (2007). "Chapter 9: Anti-inflammatory agents".Diagnosis and Management of Asthma. Professional Communications.ISBN 978-1-932610-38-3.
  31. ^abAustin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, et al. (December 2002)."Mometasone furoate is a less specific glucocorticoid than fluticasone propionate".The European Respiratory Journal.20 (6):1386–92.doi:10.1183/09031936.02.02472001.PMID 12503693.
  32. ^Walsky RL, Gaman EA, Obach RS (January 2005). "Examination of 209 drugs for inhibition of cytochrome P450 2C8".Journal of Clinical Pharmacology.45 (1):68–78.doi:10.1177/0091270004270642.PMID 15601807.S2CID 670198.
  33. ^Blaiss MS (2011). "Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis".Allergy and Asthma Proceedings.32 (6):413–8.doi:10.2500/aap.2011.32.3473.PMID 22221434.
  34. ^abElks H (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 834–.ISBN 978-1-4757-2085-3.Archived from the original on 10 January 2023. Retrieved11 March 2019.
  35. ^abIndex Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 701–.ISBN 978-3-88763-075-1.
  36. ^abMorton IK, Hall JM (31 October 1999).Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 185–.ISBN 978-0-7514-0499-9.Archived from the original on 10 January 2023. Retrieved11 March 2019.
  37. ^Vardanyan R, Hruby V (7 January 2016)."Steroid Hormones".Synthesis of Best-Seller Drugs. Elsevier Science. pp. 463–.ISBN 978-0-12-411524-8.
  38. ^"Mometasone".Archived from the original on 17 November 2016. Retrieved17 November 2016.
Glucocorticoids
Natural
Synthetic
Antiglucocorticoids
Synthesis modifiers
Decongestants and other nasal preparations (R01)
Topical
Sympathomimetics, plain
Antiallergic agents,
excluding corticosteroids
Corticosteroids
Other nasal preparations
Combination products
Systemic use:
Sympathomimetics
GRTooltip Glucocorticoid receptor
Agonists
Mixed
(SEGRMsTooltip Selective glucocorticoid receptor agonists)
Antagonists
Others
MRTooltip Mineralocorticoid receptor
Agonists
Antagonists
PRTooltip Progesterone receptor
Agonists
Mixed
(SPRMsTooltip Selective progesterone receptor modulators)
Antagonists
mPRTooltip Membrane progesterone receptor
(PAQRTooltip Progestin and adipoQ receptor)
Agonists
Antagonists
Corporate directors
Subsidiaries
Products
Schering-Plough
Facilities
Publications
Portal:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Mometasone&oldid=1315801796"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp